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Background:  In the RELAX trial, sildenafil did not improve exercise tolerance in patients with heart failure (HF) and preserved ejection 
fraction (HFpEF). However, HFpEF patients with right ventricular dysfunction (RVD) and pulmonary hypertension (PH) may be uniquely 
sensitive to sildenafil.
methods:  RELAX subjects with measureable tricuspid annular plane systolic excursion (TAPSE) and pulmonary artery systolic pressure 
(PASP) (n=137) were grouped according to RVD (TAPSE < vs ≥ 17 mm) and PH (PASP ≥ vs < 40 mmHg) at enrollment. Effect of treatment 
(placebo vs sildenafil) on change in TAPSE, peak VO2 and VE/VCO2 at 24 weeks and interaction with RVD/PH were evaluated. 
results:  See Table. At enrollment, patients with RVD tended to have worse quality of life, were more likely to have atrial fibrillation and 
use loop diuretics and had higher NT-pro BNP and worse diastolic dysfunction, exercise tolerance and ventilatory efficiency. Adjusting for 
RVD/PH group and baseline values, neither change in peak VO2 or in VE/VCO2 differed by treatment allocation (p> 0.50 for both) and with 
no interaction between RVD/PH group and treatment effect. (interaction p > 0.40 for both). Adjusting for RVD/PH, TAPSE decreased with 
Sildenafil (LSM, - 0.86 mm) vs Placebo (+ 0.87 mm, p = 0.01) with no interaction between RVD/PH group and treatment effect (p=0.59).
conclusion:  HFpEF patients with RVD and PH have more advanced HF. Sildenafil did not improve RV function, exercise capacity or 
ventilatory efficiency in this HFpEF subset.
 
